InMed Pharmaceuticals Acquires BayMedica for $10M
Ticker: INM · Form: 8-K · Filed: Jun 11, 2024 · CIK: 1728328
Sentiment: neutral
Topics: acquisition, cannabinoids, drug-development
TL;DR
InMed buys BayMedica for $10M to boost its cannabinoid drug pipeline.
AI Summary
InMed Pharmaceuticals Inc. announced on June 10, 2024, that it has entered into a definitive agreement to acquire BayMedica Inc. for approximately $10 million in cash and stock. This acquisition is expected to enhance InMed's cannabinoid drug development pipeline.
Why It Matters
This acquisition aims to strengthen InMed's position in the cannabinoid therapeutics market by integrating BayMedica's assets and expertise.
Risk Assessment
Risk Level: medium — The acquisition involves integration risks and the success of the combined drug development programs is not guaranteed.
Key Numbers
- $10.0M — Acquisition Value (Total consideration for the acquisition of BayMedica Inc.)
Key Players & Entities
- InMed Pharmaceuticals Inc. (company) — Filer and acquirer
- BayMedica Inc. (company) — Target company to be acquired
- $10 million (dollar_amount) — Acquisition price
- June 10, 2024 (date) — Date of earliest event reported
FAQ
What is the primary strategic rationale behind InMed Pharmaceuticals' acquisition of BayMedica Inc.?
The acquisition is intended to enhance InMed's cannabinoid drug development pipeline by integrating BayMedica's assets and expertise.
What is the total value of the transaction to acquire BayMedica Inc.?
The total value of the transaction is approximately $10 million, consisting of cash and stock.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 10, 2024.
What type of business is BayMedica Inc. likely involved in, given the context of the acquisition?
Given InMed's focus on cannabinoid drug development, BayMedica Inc. is likely involved in related research, development, or production of cannabinoids.
What is the principal executive office address for InMed Pharmaceuticals Inc.?
The address is Suite 310 - 815 W. Hastings Street, Vancouver, B.C. Canada V6C 1B4.
Filing Stats: 535 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-06-11 12:48:29
Filing Documents
- ea0207653-8k_inmed.htm (8-K) — 31KB
- ea020765301ex99-1_inmed.htm (EX-99.1) — 11KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-24-051625.txt ( ) — 224KB
- inm-20240610.xsd (EX-101.SCH) — 3KB
- inm-20240610_lab.xml (EX-101.LAB) — 33KB
- inm-20240610_pre.xml (EX-101.PRE) — 22KB
- ea0207653-8k_inmed_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On June 10, 2024, the Company announced that the Company will be presenting at the upcoming Emerging Growth Conference scheduled for June 12-13, 2024. The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 News release, dated June 10, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMED PHARMACEUTICALS INC. Date: June 11, 2024 By: /s/ Eric A Adams Eric A Adams President & CEO 2